Table 2.
Comparison of clinical parameters between patients with and without IP
| Patients with IP (%) | Patients without IP (%) | P | |
|---|---|---|---|
| Advanced stage | 59 (71.1%) | 43 (51.8%) | 0.011 |
| B symptom | 38 (45.8%) | 17 (20.5%) | 0.001 |
| Lung involvement | 9 (10.8%) | 7 (8.4%) | 0.599 |
| History of drug allergy | 17 (20.5%) | 7 (8.4%) | 0.027 |
| History of cigarette smoking | 13 (15.7%) | 26 (31.3%) | 0.017 |
| Diabetes mellitus | 8 (9.6%) | 8 (9.6%) | 1.0 |
| Autoimmune disease | 3 (3.6%) | 2 (2.4%) | 0.650 |
| ECOG > 1 | 6 (7.2%) | 1 (1.2%) | 0.053 |
| Extranodal involvement | 65 (78.3%) | 56 (67.5%) | 0.116 |
| Rituximab | 56 (67.5%) | 47 (56.6%) | 0.150 |
| Bleomycin | 7 (8.4%) | 7 (8.4%) | 1.000 |
| ALC < 1 × 109/L | 20 (24.1%) | 15 (18.1%) | 0.341 |
ALC, absolute lymphocyte count; ECOG, Eastern Cooperative Oncology Group; IP, interstitial pneumonia